Clinical updates in advancements of treatment of TNBC, HR+, HER2+, HER2-Low breast cancer ESMO Congress Updates - Germany
| Target Professions: | DO, MBBS, MD, Nurse Practitioner, Physician Assistant, Pharmacist |
| Target Specialties: | Gynecologic Oncology, Oncology |
| Credits Available: | 4.50 AMA PRA Category 1 Credit™ |
This curriculum aims to evaluate the landscape of BC management, delving into the latest breakthroughs, therapies, and strategies that have transformed our approach to this complex and chronic condition.
This curriculum is designed to offer you a thorough understanding of the wide range of treatment modalities available. From conventional methods to cutting-edge innovations, our goal is to equip you with the insights needed to make informed decisions for optimizing BC management, including use of ADCs, immunotherapy, PARP-inhibitors and a potential therapeutic algorithm for HER 2-low breast cancer.
CME/CE Accreditation Information
Itinerary
Part 1
We will explore the most recent evidence-based recommendations, guidelines, and clinical trial presentations of HR+ BC, ADCs, immunotherapy, and Parp-inibithors on management of patients with BC. We will identify the therapeutic algorithm for patients with HER2 low breast cancer.
At the end of this educational activity, you should have a clear picture of the latest clinical updates in advancements of treatment of TNBC, HR+, HER2+, HER2-Low BC (breast cancer).
This module is designed to offer healthcare professionals a thorough understanding of the wide range of treatment modalities available.
Now that you've covered the self-study modules, go ahead and tackle the following questions to evaluate your grasp on breast cancer management.
Part 2
This activity features a 55-year old woman who presents to your clinic today with symptoms of breast cancer. This patient case activity discusses strategies to initiate chemotherapy for the treatment of the early TNBC.
This session offers oncology clinicians and specifically those actively involved in the treatment of breast cancer a unique platform to collectively explore and address the challenges of managing breast cancer through sharing intriguing patient cases.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with TNBC, HR+, HER2+, HER2-Low BC (breast cancer).
This live group discussion, will focus on the educational content in the Self Study Modules, the Patient Case Group Challenge, and the Group Project.
Interested in becoming a Group Leader?
Group leaders should be experts in the treatment of TNBC, HR+, HER2+, HER2-Low BC (breast cancer). Apply Now
